From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Fusion Antibodies – argues trading “positive momentum”, but how positive really?

By Steve Moore | Thursday 4 July 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Antibody contract research company Fusion Antibodies (FAB) has issued a “Trading update” highlighting “Positive momentum through the first quarter of the current financial year ending 31 March 2025… continuing confidence for growth in the remainder of FY2025”. So what of a share price slightly up to 3.15p, but comparing to rising above 6p as recently as January?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Sunday »

Quiz

The ShareProphets Sunday Pub Quiz #248

Thursday »

CCT

Character Group – a Buy?

 

ING

Ingenta – now a Buy again?

 

Clown

Which PR genius wrote this?

 

HAT

H&T Group – now again a Buy

Time left: 11:29:59